Journals / Türk Biyokimya Dergisi / 2015 / Cilt: 40 - Sayı: 5

Vitiligo'da paroksinaz-1 (PON1) gen polimorfizminin araştırılması

Analysis of paraoxonase-1 (PON1) gene polymorphisms in vitiligo

Pages
356–362
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Even though there were no differences between patients and controls, this is the first study that investigated the possible associations between the PON1 M/L55 and PON Q192R gene polymorphisms within the Turkish population.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Vitiligo is a chronic autoimmune depigmentation disease, which is characterized by loss of function of the melanocytes in epidermis.
📊
Key Findings & Data:We aimed to investigate possible associations between vitiligo and PON1 M / L55 and PON Q192R gene polymorphisms in the Turkish community.Methods: The 57 patients with vitiligo and 69 healthy controls were enrolled into the study.
💡
Conclusion & Impact:Conclusion: Even though there were no differences between patients and controls, this is the first study that investigated the possible associations between the PON1 M/L55 and PON Q192R gene polymorphisms within the Turkish population.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Vitiligo is a chronic autoimmune depigmentation disease, which is characterized by loss of function of the melanocytes in epidermis. Recent studies suggest that oxidant/antioxidant status plays important role in the pathogenesis of vitiligo. We aimed to investigate possible associations between vitiligo and PON1 M / L55 and PON Q192R gene polymorphisms in the Turkish community.Methods: The 57 patients with vitiligo and 69 healthy controls were enrolled into the study. Genotyping was performed to identify PON1 M / L55 and PON Q192R gene polymorphism. Genotype and allele frequencies were compared between patients with vitiligo and healthy control group.Results: In patients (p=0.0061) and healthy controls (p=0.550), there was no significant statistical difference between L55M and Q192R polymorphisms of the PON1 gene. However, when L55M polymorphism was compared to MM homozygous genotype and LL+LM genotypes, it was notably higher in controls than in patients, which seems to be protective against the disease (p=0.034, OR:0. 3, 95% CU: 0.08-0.93). Although, there was no not a statistical difference in allele frequencies of Q192R polymorphism between patients and controls (p=0.242), the M allele of L55M polymorphism was significantly higher in controls than in patients with vitiligo, which means that it might be protective against vitiligo (p=0.009, OR: 0.48, 95% CI: 0.27-0.84). Conclusion: Even though there were no differences between patients and controls, this is the first study that investigated the possible associations between the PON1 M/L55 and PON Q192R gene polymorphisms within the Turkish population.

Özet

Amaç: Vitiligo epidermisde melanositlerin fonksiyon kaybı ile karakterize kronik otoimmün bir depigmentasyon hastalığıdır. Son çalışmalar oksidan / antioksidan durumum vitiligo patogenezinde önemli bir rol oynadığını ileri sürmektedir. Bu çalışmada, Türk toplumunda vitiligo ile PON1 M/L55 ve PON Q192R gen polimorfizmlerinin olası ilişkisini araştırmayı amaçladık.Metod: Çalışmaya vitiligolu 57 hasta ve 69 sağlıklı kontrol alındı. Genotipleme PON1 M / L55 ve PON Q192R gen polimorfizmlerinin belirlenmesi amacıyla yapılmıştır. Genotip ve allel frekansları vitiligo ve sağlıklı kontrol grubunda olan hastalar arasında karşılaştırıldı.Bulgular: Hastalarda (p=0,061) ve kontroller (p=0,550) arasında PON1 geninin L55M ve Q192R polimorfizmlerinde istatistiksel olarak anlamlı bir farklılık yoktu. Ancak L55M polimorfizmi, MM homozigot genotipi, LL+LM genotipleri ile karşılaştırıldığında hastalara göre kontrollerde, anlamlı olarak daha yüksek bulundu ve bu hastalığa karşı koruyucu olduğu görüldü (p=0,034, OR: 0,3, %95 CI: 0,08-0,93). Hastalar ve kontrol arasında Q192R polimorfizminin alel frekanslarında istatistiksel olarak anlamlı bir fark yoktu (p=0,242). Ancak L55M polimorfizminin M alellinin kontrollerde hastalara göre istatistiksel olarak anlamlı derecede yüksek olduğu ve ayrıca bu alellin hastalığa karşı koruyucu olduğu gösterildi (p=0,009, OR:0,48, %95 CI: 0,27-0,87).Sonuç: Hasta ve kontrol grubu arasında anlamlı bir fark olmamasına rağmen bu çalışma Türk popülasyonunda vitiligo ile PON1 M/L55 ve PON Q192R gen polimorfizmi arasındaki olası ilişkiyi araştıran ilk çalışmadır

🔖

Cite This Article

KARAKUŞ, N., SEÇKİN, H. Y., TAKÇI, Z., BÜTÜN, İ., BENLİ, İ., KALKAN, G., BAŞ, Y. (2022). Vitiligo'da paroksinaz-1 (PON1) gen polimorfizminin araştırılması. Türk Biyokimya Dergisi, Cilt: 40 - Sayı: 5, 356–362. https://ajindex.com/articles/621123

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Odom RB, James WD, Berger TG. Disturbance of pigmentation. Andrew's Diseases of the skin. W.B. saunders Co., Philadelphia, 2000: 1057-72.
  2. Mosher DB, Fitzpatrick TB, Ortonne JP, Yoshiaki H. Hypome- lanoses and hypermelanoses. In: Freedberg IM, Eisen AZ, Wolff K et al., eds. Dermatology in General Medicine. McGraw-Hill, New York 1999: 945-1017. singh s, singh U, Pandey ss. Increased level of serum Homocysteine in vitiligo. J Clin Lab Anal 2011; 25(2):110-2. Nordlund JJ. The epidemiology and genetics of vitiligo. Clin Dermatol 1997; 15(6):875-8.
  3. Beazley WD, Gaze D, Panske A, Panzig E, schallreuter KU. serum selenium levels and blood glutathione peroxidase activities in vitiligo. Br J Dermatol 1999; 141(2):301-3. schallreuter KU, Wood JM, Berger J. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 1991; 97(6):1081-5.
  4. Picardo M, Passi s, Morrone A, Grandinetti M, Di Carlo A, et al. Antioxidant status in the blood of patients with active vitiligo. Pigment Cell Res 1994; 7(2):110-5.
  5. Passi s, Grandinetti M, Maggio F, stancato A, De Luca C. Epidermal oxidative stress in vitiligo. Pigment Cell Res 1998; 11(2):81-5. schallreuter KU, Moore J, Wood JM, Beazley WD, Peters EM, et al. Epidermal H(2)O(2) accumulation alters tetrahydrobi- opterin (6BH4) recycling in vitiligo: identification of a general mechanism in regulation of all 6BH4-dependent processes? J Invest Dermatol 2001; 116(1):167-74.
  6. Hazneci E, Karabulut AB, Oztürk C, Batçioğlu K, Doğan G, et al. A comparative study of superoxide dismutase, catalase, and glutathione peroxidase activities and nitrate levels in vitiligo patients. Int J Dermatol 2005; 44(8):636-40.
  7. Yildirim M, Baysal V, Inaloz Hs, Kesici D, Delibas N. The role of oxidants and antioxidants in generalized vitiligo. J Dermatol 2003; 30(2):104-8.
  8. Arican O, Kurutas EB. Oxidative stress in the blood of patients with active localized vitiligo. Acta Dermatovenerol Alp Pannonica Adriat 2008; 17(1):12-6.
  9. Akoglu G, Emre s, Metin A, Akbas A, Yorulmaz A, et al. Evaluation of total oxidant and antioxidant status in localized and generalized vitiligo. Clin Exp Dermatol 2013; 38(7):701-6.
  10. Bickers DR, Athar M. Oxidative stress in the pathogenesis of skin disease. J Invest Dermatol 2006; 126(12):2565-75.
  11. Briganti s, Picardo M. Antioxidant activity, lipid peroxidation and skin diseases. What's new. J Eur Acad Dermatol Venereol 2003; 17(6):663-9.
  12. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistr